Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Merck
Scientific Title
A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants With First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)